Article ; Online: The 4
Pediatric rheumatology online journal
2024 Volume 21, Issue Suppl 1, Page(s) 79
Abstract: Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that ...
Abstract | Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising "lead" for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies. |
---|---|
MeSH term(s) | Humans ; Arthritis, Juvenile/drug therapy ; Interleukin-18 ; Consensus ; Disease Progression ; Biomarkers |
Chemical Substances | Interleukin-18 ; Biomarkers |
Language | English |
Publishing date | 2024-01-05 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 2279468-2 |
ISSN | 1546-0096 ; 1546-0096 |
ISSN (online) | 1546-0096 |
ISSN | 1546-0096 |
DOI | 10.1186/s12969-023-00867-y |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.